Tracey L. McCain Esq.
Net Worth
Last updated:
What is Tracey L. McCain Esq. net worth?
The estimated net worth of Ms. Tracey L. McCain Esq. is at least $18,638,607 as of 7 Mar 2024. She owns shares worth $7,832,071 as insider, has earned $5,788,726 from insider trading and has received compensation worth at least $5,017,810 in Blueprint Medicines Corporation.
What is the salary of Tracey L. McCain Esq.?
Ms. Tracey L. McCain Esq. salary is $716,830 per year as Executive Vice President, Chief Legal Officer, Chief Compliance officer & Sec. in Blueprint Medicines Corporation.
How old is Tracey L. McCain Esq.?
Ms. Tracey L. McCain Esq. is 57 years old, born in 1968.
What stocks does Tracey L. McCain Esq. currently own?
As insider, Ms. Tracey L. McCain Esq. owns shares in one company:
| Company | Title | Shares | Price per share | Total value |
|---|---|---|---|---|
| Blueprint Medicines Corporation (BPMC) | Executive Vice President, Chief Legal Officer, Chief Compliance officer & Sec. | 60,498 | $129.46 | $7,832,071 |
What does Blueprint Medicines Corporation do?
Blueprint Medicines Corporation, a precision therapy company, develops medicines for genomically defined cancers and blood disorders in the United States and internationally. The company is developing AYVAKIT for the treatment of systemic mastocytosis (SM) and gastrointestinal stromal tumors; BLU-263, an orally available, potent, and KIT inhibitor for the treatment of non-advanced SM and other mast cell disorders; and Fisogatinib, an orally available and potent inhibitor for the treatment of hepatocellular carcinoma. It is also developing GAVRETO for the treatment of RET fusion-positive non-small cell lung cancer, altered solid tumors, medullary thyroid carcinoma, and other solid tumors; BLU-701 and BLU-945 for the treatment of epidermal growth factor receptor driven non-small-cell lung carcinoma (NSCLC); and BLU-451 to treat NSCLC in patients with epidermal growth factor receptor gene (EGFR) exon 20 insertion mutations. In addition, the company is developing BLU-782, for the treatment of fibrodysplasia ossificans progressive; BLU- 222 to treat patients with cyclin E aberrant cancers; and BLU-852 for the treatment of advanced cancers. It has collaboration and license agreements with Clementia Pharmaceuticals, Inc.; Proteovant Therapeutics; CStone Pharmaceuticals; Genentech, Inc.; F. Hoffmann-La Roche Ltd and Hoffmann-La Roche Inc.; and Zai Lab (Shanghai) Co., Ltd. The company was formerly known as Hoyle Pharmaceuticals, Inc. and changed its name to Blueprint Medicines Corporation in June 2011. Blueprint Medicines Corporation was incorporated in 2008 and is headquartered in Cambridge, Massachusetts.
Tracey L. McCain Esq. insider trading
Blueprint Medicines Corporation
Ms. Tracey L. McCain Esq. has made 12 insider trades between 2018-2024, according to the Form 4 filled with the SEC. Most recently she sold 5,194 units of BPMC stock worth $471,044 on 7 Mar 2024.
The largest trade she's ever made was exercising 25,000 units of BPMC stock on 23 Sep 2021. As of 7 Mar 2024 she still owns at least 60,498 units of BPMC stock.
Blueprint Medicines key executives
Blueprint Medicines Corporation executives and other stock owners filed with the SEC:
- Dr. Fouad Namouni M.D. (56) Pres of R&D
- Mr. Alexis A. Borisy A.M. (53) Co-Founder & Director
- Mr. Jeffrey W. Albers J.D., M.B.A., MBA (54) Chairman, Chief Executive Officer & Pres
- Mr. Michael Landsittel (53) Chief Financial Officer & Treasurer
- Ms. Kathryn Haviland (49) Chief Operating Officer
- Ms. Tracey L. McCain Esq. (57) Executive Vice President, Chief Legal Officer, Chief Compliance officer & Sec.